力生製藥(002393.SZ):2024年度擬向全體股東每10股派發現金股利3.5元
格隆匯3月20日丨力生製藥(002393.SZ)公佈,公司擬定的2024年度利潤分配預案如下:公司擬以本次董事會日2025年3月19日總股本257,704,999股,扣除公司庫存股1,439,980股,即以256,265,019股爲基數,向全體股東每10股派發現金股利3.50元(含稅),實際分配利潤89,692,756.65元,佔公司2024年度歸屬於上市公司股東淨利潤184,528,445.53元的48.61%,餘額滾存至下一年度。本次利潤分配不送紅股、不進行資本公積金轉增股本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.